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I.  General Procedures 
 
NMR spectra were obtained on a Varian vnmrs 700 (699.76 MHz for 1H; 175.95 MHz for 13C; 658.43 for 
19F), Varian vnmrs 500 (500.10 MHz for 1H; 125.75 MHz for 13C, 470.56 MHz for 19F), Varian Inova 500 
(499.90 MHz for 1H; 125.70 MHz for 13C), or a Varian MR400 (400.52 MHz for 1H; 100.71 for 13C, 
376.87 MHz for 19F) spectrometer. 1H NMR chemical shifts are reported in parts per million (ppm) 
relative to TMS, with the residual solvent peak used as an internal reference.  Multiplicities are reported 
as follows: singlet (s), doublet (d), doublet of doublets (dd), doublet of doublets of doublets (ddd), doublet 
of triplets (dt), triplet (t), triplet of doublets (td), triplet of triplets (tt), quartet (q), quintet (quin), multiplet 
(m), and broad resonance (br). IR spectra were obtained on a Perkin-Elmer Spectrum BX FT-IR 
spectrometer. Melting points were determined with a Mel-Temp 3.0, a Laboratory Devices Inc, USA 
instrument, and are uncorrected. HRMS data were obtained on a Micromass AutoSpec Ultima Magnetic 
Sector mass spectrometer. Gas chromatography was carried out on a Shimadzu 17A using a Restek Rtx®-
5 (Crossbond 5% diphenyl – 95% dimethyl polysiloxane; 15 m, 0.25 mm ID, 0.25 μm df) column. GC 
calibrated yields are reported relative to hexadecane as an internal standard. 
 
Materials and Methods: Substrates 21 and 82 were prepared according to literature procedures. Substrate 
9 was prepared by a palladium-catalyzed Suzuki coupling between 2-methoxyboronic acid and 2-
bromopyridine. Oxime ethers 10 and 11 were prepared by the reaction of the corresponding ketones with 
MeONH2•HCl in pyridine.3 The remaining substrates were obtained from Aldrich (1, 5, and 7), Alfa 
Aesar (3 and 4), or Acros (6) and were used as received. [Ph2I]BF4 and [Mes–I–Ph]BF4 were prepared by 
the reaction of PhI(OAc)2 or MesI(OAc)2 with PhB(OH)2 in the presence of BF3•Et2O.4 [Ph2I]OTf and 
[Mes2I]OTf were prepared by the reaction of iodobenzene or iodomesitylene with mCPBA and benzene 
or mesitylene in the presence of TfOH.5 Unsymmetrical [Ar–I–Ph]BF4 salts were prepared by the reaction 
of an aryl iodide with m-CPBA and PhB(OH)2 in the presence of BF3•Et2O.6 Symmetrical [Ar2I]BF4 salts 
were prepared by the reaction of an aryl iodide with m-CPBA and the corresponding arylboronic acid in 
the presence of BF3•Et2O.6 Pd(OAc)2, obtained from Pressure Chemical, and Pd(NO3)2 and 
Ru(bpy)3Cl2•6H2O, obtained from Strem, were used as received. Ir(ppy)37 and Ir(ppy)2(dtbbpy)PF68 were 
prepared according to literature procedures. Solvents were obtained from Fisher Chemical and used 
without further purification. Flash chromatography was performed on EM Science silica gel 60 (0.040–
0.063 mm particle size, 230–400 mesh) and thin layer chromatography was performed on Merck TLC 
plates pre-coated with silica gel 60 F254. 
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II. Synthesis and Characterization of Products in Table 2 
 
General Procedure: Substrate (1 equiv), [Ph2I]BF4 or [Ph2I]OTf (2 equiv), Ir(ppy)2(dtbbpy)PF6 (0.05 
equiv), and Pd(NO3)2•2H2O (0.10 equiv) were combined in MeOH in a 4 mL scintillation vial. For 
substrates containing N-acetyl moieties (noted below), MgO (1 equiv) was also included and appeared to 
help prevent substrate and/or product degradation. The reaction mixture was cooled in an ice bath (to 
prevent evaporation) and sparged with N2 using a submerged needle for 10 min, and the vial was then 
immediately sealed with a Teflon-lined cap. The vial was placed on a stir plate with two 26 W compact 
fluorescent light bulbs (one on either side of the vial about 5–8 cm away), and the reaction mixture was 
allowed to stir at room temperature for 15 h. The reaction mixture was diluted with EtOAc (50 mL) and 
washed with 10% aqueous Na2SO3 (2 x 25 mL) and brine (1 x 25 mL). The combined aqueous layers 
were extracted with EtOAc (3 x 10 mL), and the organic layers were then combined, dried over MgSO4, 
filtered, concentrated, and purified by column chromatography on silica gel. 
 
Pyrrolidinone 1a. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.05 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1a was obtained as a pale 
yellow oil (96.3 mg, 81% yield, Rf = 0.17 in 20% hexanes/80% Et2O). 1H and 13C 
NMR data matched those reported in the literature.9  
 
Pyrrolidinone 2a. The general procedure was followed utilizing substrate 2 (47.8 
mg, 0.25 mmol, 1.0 equiv), [Ph2I]OTf (215 mg, 0.50 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (11.4 mg, 0.0125 mmol, 0.05 equiv), Pd(NO3)2•2H2O (6.7 mg, 
0.025 mmol, 0.10 equiv), and MeOH (1.8 mL). Product 2a was obtained as a pale 
yellow solid [62.5 mg, 94% yield, Rf = 0.10 in 20% hexanes/80% Et2O, mp = 72.9-
74.7 ºC (lit.11 61–64 ºC)]. 1H and 13C NMR data matched those reported in the literature.9 
 
Acetanilide 3a. The general procedure was followed utilizing substrate 3 (37.3 mg, 
0.25 mmol, 1.0 equiv), [Ph2I]BF4 (184 mg, 0.50 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(11.4 mg, 0.0125 mmol, 0.05 equiv), Pd(NO3)2•2H2O (6.7 mg, 0.025 mmol, 0.10 
equiv), and MeOH (1.25 mL), with the addition of MgO (10.1 mg, 0.25 mmol, 1.0 
equiv). Product 3a was obtained as a pale yellow solid [40.6 mg, 72% yield, Rf = 0.17 












7.64 (br s, 1H); 7.42–7.39 (multiple peaks, 2H); 7.35 (t, J = 7.4 Hz, 1H); 7.32–7.31 (multiple peaks, 2H); 
7.27 (d, J = 4.9 Hz, 2H); 7.17 (t, J = 4.9 Hz, 1H); 2.23 (s, 3H); 1.85 (s, 3H). 13C{1H} NMR (176 MHz, 
CD3CN): δ 170.04; 141.30; 140.97; 138.16; 134.58; 130.52; 129.67; 129.03; 128.72; 128.14; 128.05; 
22.76; 18.54. IR (thin film, CH2Cl2) 3246, 3026, 2922, 1652, 1522 cm-1. HRMS [M+H]+ Calcd for 
C15H16NO: 226.1226; Found: 226.1234. 
 
Acetylindoline 4a. The general procedure was followed utilizing substrate 4 (80.5 mg, 
0.50 mmol, 1.0 equiv), [Ph2I]BF4 (368 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (26.6 mg, 0.100 mmol, 0.20 
equiv), and MeOH (2.5 mL), with the addition of MgO (20.2 mg, 0.50 mmol, 1.0 
equiv). Product 4a was obtained as a pale yellow solid [51.7 mg, 44% yield, Rf = 0.30 
in 20% hexanes/80% Et2O, mp = 116.3-117.8 ºC (lit. 117-119 ºC)].11 1H and 13C NMR data matched those 
reported in the literature.11  
 
Benzamide 5a. The general procedure was followed utilizing substrate 5 (33.8 mg, 
0.50 mmol,  1.0 equiv), [Ph2I]BF4 (368 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.050 mmol, 0.10 
equiv), and MeOH (2.5 mL). Product 5a was obtained as a white solid (39 mg, 40% 
yield, Rf = 0.26 in 1:1:1 benzene:CH2Cl2:Et2O, mp = 169.0-173.0 ºC). 1H NMR (700 
MHz, CDCl3): δ 7.79 (d, J = 7.7 Hz, 1H), 7.50 (td, J = 7.7, 0.7 Hz, 1H), 7.46-7.42 (multiple peaks, 5H), 
7.39 (m, 1H), 7.37 (dd, J = 7.7, 0.7 Hz, 1H), 5.62 (br s, 1H), 5.25 (br s, 1H).  13C{1H} NMR (176 MHz, 
CDCl3): δ 171.21, 140.15, 139.80, 134.30, 130.54, 130.38, 129.08, 128.77, 128.69, 127.93, 127.62. IR 
(thin film, CDCl3) 3383, 3178, 1653, 1643 cm-1. HRMS [M+H]+ Calcd for C13H12NO: 198.0913; Found: 
198.0920. 
 
Benzamide 6a. The general procedure was followed utilizing substrate 6 (67.6 mg, 
0.50 mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.05 mmol, 0.10 
equiv), and MeOH (2.5 mL). Product 6a was obtained as a pale yellow solid (56.7 mg, 
54% yield, Rf = 0.27 in 20% hexanes/80% Et2O, mp = 164.5-166.8 ºC). 1H NMR (400 
MHz, CDCl3): δ 7.69 (dd, J = 7.6, 1.6 Hz, 1H), 7.47 (td, J = 7.6, 1.2 Hz, 1H), 7.42-7.35 (multiple peaks, 
7H), 5.19 (br s, 1H), 2.67 (d, J = 4.8 Hz, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 170.24, 140.12, 











3286, 3060, 2936, 1636, 1540, 1313 cm-1. HRMS [M+H]+ Calcd for C14H14NO: 212.1070; Found: 
212.1074. 
 
Benzamide 7a. The general procedure was followed utilizing substrate 7 (74.6 mg, 
0.50 mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.05 mmol, 0.10 equiv), 
and MeOH (2.5 mL). Product 7a was obtained as a yellow oil (9.8 mg, 9% yield, Rf = 
0.27 in 20% hexanes/80% Et2O). 1H NMR (400 MHz, CDCl3): δ 7.48-7.44 (multiple 
peaks, 3H), 7.42-7.32 (multiple peaks, 6H), 2.85 (s, 3H), 2.39 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): 
δ 171.33, 139.93, 138.67, 135.74, 129.30, 128.47, 128.36, 127.70, 127.58, 127.41, 37.94, 24.53. Two 
aromatic 13C resonances are coincidentally overlapping. IR (thin film, CDCl3) 3057, 2924, 1624, 1394 
cm-1. HRMS [M+H]+ Calcd for C15H16NO: 226.1226; Found: 226.1232. 
 
Pyridine 8a. The general procedure was followed utilizing substrate 8 (84.6 mg, 0.50 
mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 (22.8 
mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.050 mmol, 0.10 equiv), and 
MeOH (2.5 mL). Product 8a was obtained as a clear viscous oil (76.0 mg, 62% yield, 
Rf = 0.09 in 90% hexanes/10% Et2O). 1H and 13C NMR data matched those reported in 
the literature.9  
 
Pyridine 9a. The general procedure was followed utilizing substrate 9 (92.6 mg, 0.50 
mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 (22.8 
mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.050 mmol, 0.10 equiv), 
and MeOH (2.5 mL). Product 9a was obtained as a pale yellow solid [88.0 mg, 67% 
yield, Rf = 0.11 in 60% hexanes/40% Et2O, mp = 83.5-86.4 ºC (lit. 77.7-85.4 ºC)].9 1H 
and 13C NMR data matched those reported in the literature.9  
 
Oxime ether 10a. The general procedure was followed utilizing substrate 10 (81.6 mg, 
0.50 mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.050 mmol, 0.10 
equiv), and MeOH (2.5 mL). Product 10a was obtained as a colorless oil (71.4 mg, 
60% yield, Rf = 0.14 in 98% hexanes/2% Et2O). 1H NMR (700 MHz, CDCl3): δ 7.39–
7.36 (multiple peaks, 4H), 7.32 (m, 1H), 7.29 (d, J = 7.7 Hz, 1H), 7.23 (dd, J = 7.0, 0.7 Hz, 1H), 7.20 (dd, 













141.21, 140.97, 136.19, 136.07, 129.38, 129.34, 128.13, 127.94, 127.63, 126.92, 61.62, 20.08, 16.56. IR 
(thin film, neat) 3060, 2936, 1459, 1041 cm-1. HRMS [M+H]+ Calcd for C16H18NO: 240.1383; Found: 
240.1387. 
Oxime ether 11a. The general procedure was followed utilizing substrate 11 (74.6 mg, 
0.50 mmol, 1.0 equiv), [Ph2I]OTf (430 mg, 1.00 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 
(22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 0.050 mmol, 0.10 
equiv), and MeOH (2.5 mL). Product 11a was obtained as a colorless oil consisting of 
a ~1.5:1 mixture of oxime stereoisomers (64.7 mg, 57% yield, Rf = 0.28 (major) and 
0.14 (minor) in 6:1:0.2 hexanes/benzene/methylene chloride). Major Isomer: 1H NMR (700 MHz, C6D6): 
δ 8.26 (s, 1H); 7.22 (m, 2H), 7.09 (tt, J = 7.4, 1.4 Hz, 2H); 7.06-7.05 (multiple peaks, 2H); 7.04-7.02 
(multiple peaks, 2H); 3.76 (s, 3H), 2.62 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 149.09, 143.18, 
140.66, 137.83, 130.33, 129.83, 128.48, 128.12, 127.84, 127.21, 61.85, 22.46. Two aromatic 13C 
resonances are coincidentally overlapping. IR (thin film, neat) 3059, 2935, 1460, 1048 cm-1. HRMS 
[M+H]+ Calcd for C15H16NO: 226.1226; Found: 226.1227. Minor Isomer: 1H NMR (700 MHz, C6D6): δ 
7.40 (d, J = 7.7 Hz, 2H); 7.24 (s, 1H); 7.19 (t, J = 7.7 Hz, 2H); 7.13-7.10 (multiple peaks, 2H); 7.08 (t, J = 
7.7 Hz, 1H); 6.98 (d, J = 7.7 Hz, 1H); 3.66 (s, 3H); 2.22 (s, 3H). 13C{1H} NMR (100 MHz, CDCl3): δ 
147.58, 140.70, 140.66, 136.43, 130.19, 128.87, 128.84, 128.74, 128.05, 127.36, 126.99, 61.79, 20.13. IR 







III. Synthesis and Characterization of Products in Table 3 
General Procedure: Substrate (1 equiv), [Ar2I]BF4 (2 equiv), Ir(ppy)2(dtbbpy)PF6 (0.05 equiv), and 
Pd(NO3)2•2H2O (0.10 equiv) were combined in MeOH in a 4 mL scintillation vial. The reaction mixture 
was cooled in an ice bath (to prevent evaporation) and sparged with N2 using a submerged needle for 10 
min, and the vial was then immediately sealed with a Teflon-lined cap. The vial was placed on a stir plate 
with two 26 W compact fluorescent light bulbs (one on either side of the vial about 5–8 cm away), and 
the reaction mixture was allowed to stir at room temperature for 15 h. The reaction mixture was diluted 
with EtOAc (50 mL) and washed with 10% aqueous Na2SO3 (2 x 25 mL) and brine (1 x 25 mL). The 
combined aqueous layers were extracted with EtOAc (3 x 10 mL), and the organic layers were then 
combined, dried over MgSO4, filtered, concentrated, and purified by column chromatography on silica 
gel. 
Pyrrolidinone 1b. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(p-CF3C6H4)2I]BF4 (504 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1b was obtained as a tan 
solid [106 mg, 69% yield, Rf = 0.17 in 20% hexanes/80% Et2O, mp = 87.6-89.2 ºC 
(lit. 86.1–88.0 ºC)].9 1H and 13C NMR data matched those reported in the literature.9  
Pyrrolidinone 1c. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(m-CF3C6H4)2I]BF4 (504 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1c was obtained as a tan 
solid [86.1 mg, 56% yield, Rf = 0.23 in 20% hexanes/80% Et2O, mp = 79.2-83.5  ºC]. 
1H NMR (700 MHz, CDCl3): δ 7.64 (br s, 1H), 7.62 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 7.7 Hz, 1H), 7.53 (t, 
J = 7.7 Hz, 1H), 7.45 (m, 1H), 7.41–7.40 (multiple peaks, 2H), 7.33 (d, J = 7.7 Hz, 1H), 3.28 (t, J = 7.0 
Hz, 2H), 2.40 (t, J = 8.1 Hz, 2H), 1.91 (tt, J = 8.1, 7.0 Hz, 2H). 13C{1H} NMR (176 MHz, CDCl3): δ 
175.42, 139.84, 138.11, 136.29, 131.80, 130.71 (q, JC–F = 32 Hz), 130.60, 129.25, 128.96, 128.30, 128.25, 
124.99 (q, JC–F = 3.6 Hz), 124.21 (q, JC–F = 3.8 Hz), 123.97 (q, JC–F = 272 Hz), 50.30, 30.93, 18.83. 19F 
NMR (376 MHz, CDCl3): δ –62.65 (s). IR (thin film, CDCl3) 2918, 1692, 1333, 1117 cm-1. HRMS 








Pyrrolidinone 1d. The general procedure was followed utilizing substrate 1 (40.3 
mg, 0.25 mmol, 1.0 equiv), [(o-CF3C6H4)2I]BF4 (252 mg, 0.50 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (11.4 mg, 0.0125 mmol, 0.05 equiv), Pd(NO3)2•2H2O (6.7 mg, 
0.025 mmol, 0.10 equiv), and MeOH (1.25 mL). Product 1d was obtained as a 
white solid (35.0 mg, 46% yield, Rf = 0.13 in 20% hexanes/80% Et2O, mp = 61.8-
63.9 ºC). 1H NMR (700 MHz, CDCl3): δ 7.76 (d, J = 7.7 Hz, 1H), 7.54 (t, J = 7.7 Hz, 1H), 7.49 (t, J = 7.7 
Hz, 1H), 7.46 (td, J = 7.7, 1.4 Hz, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.36 (td, J = 7.4, 1.4 Hz, 1H), 7.33–7.32 
(multiple peaks, 2H), 3.36 (ddd, J = 14.0, 7.7, 5.6 Hz, 1H), 3.03 (ddd, J = 14.0, 8.4, 5.6 Hz, 1H), 2.40 
(ddd, J = 16.4, 9.1, 6.3 Hz, 1H), 2.22 (ddd, J = 16.4, 9.1, 6.3 Hz, 1H), 1.94 (m, 1H), 1.67 (m, 1H). 
13C{1H} NMR (176 MHz, CDCl3): δ 175.57, 137.43, 136.99, 136.76, 132.08, 131.25, 131.05 (q, JC–F = 
2.1 Hz), 129.25, 128.28 (q, JC–F = 30 Hz), 128.08, 127.96, 127.17, 126.21 (q, JC–F = 5.3 Hz), 124.06 (q, 
JC–F = 274 Hz), 49.90, 30.98, 19.05. 19F NMR (376 MHz, CDCl3): δ –57.09 (s). IR (thin film, CDCl3) 
2920, 1697, 1313, 1111 cm-1. HRMS [M+H]+ Calcd for C17H15F3NO: 306.1100; Found: 306.1112. 
Pyrrolidinone 1e. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(p-ClC6H4)2I]BF4 (437 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1e was obtained as a tan 
solid [104 mg, 77% yield, Rf = 0.13 in 20% hexanes/80% Et2O, mp = 95.6-97.4 ºC 
(lit. 93.9-96.0 ºC)].9 1H and 13C NMR data matched those reported in the literature.9  
Pyrrolidinone 1f. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(p-BrC6H4)2I]BF4 (526 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1f was obtained as a pale 
yellow oil (125 mg, 79% yield, Rf = 0.13 in 20% hexanes/80% Et2O). 1H NMR (500 
MHz, CDCl3): δ 7.54 (d, J = 8.5 Hz, 2H), 7.44–7.35 (multiple peaks, 3H) 7.33 (d, J 
= 7.5 Hz, 1H), 7.27 (d, J = 8.5 Hz, 2H), 3.27 (t, J = 7.0 Hz, 2H), 2.44 (t, J = 8.0 Hz, 2H), 1.93 (tt, J = 8.0, 
7.0 Hz, 2H). 13C{1H} NMR (126 MHz, CDCl3): δ 175.61, 138.48, 138.01, 136.18, 131.56, 130.61, 
130.00, 128.95, 128.40, 128.18, 121.87, 50.26, 31.09, 18.94. IR (thin film, neat) 2879, 1680, 1402 cm-1. 












Pyrrolidinone 1g. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(p-MeC6H4)2I]BF4 (396 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1g was obtained as a tan solid 
(109.8 mg, 87% yield, Rf = 0.17 in 20% hexanes/80% Et2O, mp = 78.6-80.4 ºC). 1H 
NMR (700 MHz, CDCl3): δ 7.40-7.35 (multiple peaks, 3H), 7.31 (d, J = 7.3 Hz, 1H), 
7.27 (d, J = 8.0 Hz, 2H), 7.20 (d, J = 8.0 Hz, 2H), 3.22 (t, J = 6.9 Hz, 2H), 2.43 (t, J = 8.0 Hz, 2H), 2.39 
(s, 3H), 1.88 (tt, J = 8.0, 6.9 Hz, 2H). 13C{1H} NMR (176 MHz, CDCl3): δ 175.61, 139.52, 137.28, 
136.27, 136.16, 130.86, 129.12, 128.34, 128.30, 128.18, 127.98, 50.06, 31.20, 21.18, 18.97. IR (thin film, 
CDCl3) 3026, 2920, 1694, 1487, 1407, 1301 cm-1. HRMS [M+H]+ Calcd for C17H18NO: 252.1383; Found: 
252.1391. 
 
Pyrrolidinone 1h. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(o-MeC6H4)2I]BF4 (396 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1h was obtained as a pale 
yellow oil (107 mg, 85% yield, Rf = 0.20 in 20% hexanes/80% Et2O). NMR (500 
MHz, CDCl3): δ 7.40 (ddd, J = 7.7, 7.0, 1.4 Hz, 1H), 7.36 (dd, J = 8.4, 1.4 Hz, 1H), 7.34 (td, J = 7.7, 1.4 
Hz, 1H), 7.27–7.24 (multiple peaks, 3H), 7.19 (m, 1H), 7.16 (d, 7.0 Hz, 1H), 3.23 (ddd, J = 9.1, 8.4, 5.6 
Hz, 1H), 3.09 (ddd, J = 9.1, 7.7, 5.6 Hz, 1H) 2.32 (m, 2H), 2.15 (s, 3H), 1.82 (m, 1H), 1.75 (m, 1H). 
13C{1H} NMR (126 MHz, CDCl3): δ 175.10, 138.89, 138.60, 136.96, 135.88, 131.11, 130.13, 129.39, 
128.3, 128.1, 127.72, 127.29, 125.47, 49.94, 31.15, 19.93, 19.02. IR (thin film, neat) 2952, 1696, 1398 
cm-1. HRMS [M+H]+ Calcd for C17H18NO: 252.1383; Found: 252.1392. 
Pyrrolidinone 1i. The general procedure was followed utilizing substrate 1 (40.3 
mg, 0.25 mmol, 1.0 equiv), [Mes2I]OTf (257 mg, 0.50 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (11.3 mg, 0.0125 mmol, 0.05 equiv), Pd(NO3)2•2H2O (6.7 
mg, 0.025 mmol, 0.10 equiv), and MeOH (1.25 mL). Product 1i was obtained as a 
white solid (8 mg, 11% yield, Rf = 0.17 in 96% CH2Cl2/4% Et2O, mp = 121.2-
123.8 ºC). 1H NMR (700 MHz, CDCl3): δ 7.44–7.39 (multiple peaks, 2H), 7.34 
(td, J = 7.5, 1.5 Hz, 1H), 7.13 (dd, J = 7.5, 1.2 Hz, 1H), 6.92 (s, 2H), 3.12 (t, J = 6.9 Hz, 2H), 2.36 (t, J = 
8.0 Hz, 2H), 2.34 (s, 3H), 1.98 (s, 6H), 1.80 (tt, J = 8.0, 6.9 Hz, 2H). 13C{1H} NMR (176 MHz, CDCl3): δ 














21.06, 20.41, 19.07. IR (thin film, CH2Cl2) 2918, 1699, 1398, 1301 cm-1. HRMS [M+H]+ Calcd for 
C19H22NO: 280.1699; Found: 280.1705. 
 
Pyrrolidinone 1j. The general procedure was followed utilizing substrate 1 (80.6 
mg, 0.50 mmol, 1.0 equiv), [(p-OMeC6H4)2I]BF4 (428 mg, 1.00 mmol, 2 equiv), 
Ir(ppy)2(dtbbpy)PF6 (22.8 mg, 0.025 mmol, 0.05 equiv), Pd(NO3)2•2H2O (13.3 mg, 
0.050 mmol, 0.10 equiv), and MeOH (2.5 mL). Product 1j was obtained as a tan 
viscous oil (54.3 mg, 41% yield, Rf = 0.07 in 20% hexanes/80% Et2O). 1H and 13C 






IV. Experimental Details for Table 4 
 
Radical/Photocatalytic Procedure for Reactions in Table 4 (entries 1–5): Substrate 8 (8.5 mg, 0.050 
mmol, 1 equiv), [Ph2I]BF4 (36.8 mg, 0.100 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 (2.3 mg, 0.0025 mmol, 
0.05 equiv), Pd(NO3)2•2H2O (1.3 mg, 0.005 mmol, 0.10 equiv), and galvinoxyl (0, 2.1, or 5.3 mg; 0, 
0.005, or 0.0125 mmol; 0, 0.10, or 0.25 equiv) or TEMPO (0, 3.9, or 7.8 mg; 0, 0.025, or 0.050 mmol; 0, 
0.50, or 1.0 equiv) were combined in MeOH (0.25 mL) in a 4 mL scintillation vial. The reaction mixture 
was cooled in an ice bath (to prevent evaporation) and sparged with N2 using a submerged needle for 1 
min, and the vial was then immediately sealed with a Teflon-lined cap. The vial was placed on a stir plate 
with two 26 W compact fluorescent light bulbs (one on either side of the vial about 5–8 cm away), and 
the reaction mixture was allowed to stir at room temperature for 15 h. Reactions were then quenched with 
10% aqueous Na2SO3 (0.25 mL), diluted with EtOAc (3.5 mL), and analyzed by GC-FID. GC calibrated 
yields are reported relative to hexadecane as an internal standard. The yields reported in Table 4 are the 
averages of three separate trials. 
 
Ionic/Thermal Procedure for Reactions in Table 4 (entries 6–9). Substrate 8 (8.5 mg, 0.050 mmol, 1 
equiv), [Ph2I]BF4 (20.2 mg, 0.055 mmol, 1.1 equiv), Pd(OAc)2 (1.1 mg, 0.005 mmol, 0.10 equiv), and 
galvinoxyl (0 or 5.3 mg; 0 or 0.0125 mmol; 0 or 0.25 equiv) or TEMPO (0 or 7.8 mg; 0 or 0.050 mmol; 0 
or 1.0 equiv) were combined in AcOH (0.42 mL) in a 4 mL scintillation vial. The reaction was heated to 
100 ºC for 15 h, then quenched with 10% aqueous Na2SO3 (0.25 mL), diluted with EtOAc (3.5 mL), and 
analyzed by GC-FID. GC calibrated yields are reported relative to hexadecane as an internal standard. 
The yields reported in Table 4 are the averages of three separate trials. These conditions are similar to 
those reported previously for 2-arylpyridine substrates;11 however, the catalyst loading was increased to 
10% (instead of 5%) to more closely resemble the conditions of the photocatalytic/radical trials. 
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V. Experimental Details for Equation 1 
 
 
Radical/Photocatalytic Procedure for Reaction in Equation 1. Substrate 1 (8.1 mg, 0.050 mmol, 1 
equiv), [(o-CF3C6H4)–I–Ph]BF4 (43.6 mg, 0.100 mmol, 2 equiv), Ir(ppy)2(dtbbpy)PF6 (2.3 mg, 0.0025 
mmol, 0.05 equiv), and Pd(NO3)2•2H2O (1.3 mg, 0.005 mmol, 0.10 equiv) were combined in MeOH (0.25 
mL) in a 4 mL scintillation vial. The reaction mixture was cooled in an ice bath (to prevent evaporation) 
and sparged with N2 using a submerged needle for 1 min, and the vial was then immediately sealed with a 
Teflon-lined cap. The vial was placed on a stir plate with two 26 W compact fluorescent light bulbs (one 
on either side of the vial about 5–8 cm away), and the reaction mixture was allowed to stir at room 
temperature for 15 h. Reactions were then quenched with 10% aq. Na2SO3 (0.25 mL), diluted with EtOAc 
(3.5 mL), and analyzed by GC-FID. GC calibrated yields are reported relative to hexadecane as an 
internal standard. 
 
Ionic/Thermal Procedure for Reaction in Equation 1. Substrate 1 (8.1 mg, 0.050 mmol, 1 equiv), [(o-
CF3C6H4)–I–Ph]BF4 (43.6 mg, 0.100 mmol, 2 equiv), Pd(OAc)2 (1.1 mg, 0.005 mmol, 0.10 equiv), and 
NaHCO3 (6.3 mg, 0.075 mmol, 1.5 equiv) were combined in toluene (0.42 mL). The reaction was heated 
to 100 ºC for 15 h, then quenched with 10% aq. Na2SO3 (0.25 mL), diluted with EtOAc (3.5 mL), and 
analyzed by GC-FID. GC calibrated yields are reported relative to hexadecane as an internal standard. 
These conditions are similar to the conditions reported previously for substrate 1;11 however, the 
equivalents of oxidant were increased to 2 (instead of 1.5) and the catalyst loading was increased to 10% 




VI. Experimental Details for Table 5 
 
 
PhN2+ procedure.9 Substrate (0.050 mmol, 1 equiv), Pd(OAc)2 (1.1 mg, 0.005 mmol, 0.10 equiv), 
Ru(bpy)3Cl2•6H2O (0.94 mg, 0.00125 mmol, 0.025 equiv), and [PhN2]BF4 (38.4 mg, 0.200 mmol, 4 
equiv) were combined in MeOH (500 µL) in a 4 mL scintillation vial. The reaction mixture was cooled in 
an ice bath (to prevent evaporation) and sparged with N2 using a submerged needle for 1 min, and the vial 
was then immediately sealed with a Teflon-lined cap. The vial was placed on a stir plate with two 26 W 
compact fluorescent light bulbs (one on either side of the vial about 5–8 cm away), and the reaction 
mixture was allowed to stir at room temperature for 15 h. Reactions were then quenched with 10% aq. 
Na2SO3 (0.25 mL), diluted with EtOAc (3.5 mL), and analyzed by GC-FID. GC calibrated yields are 
reported relative to hexadecane as an internal standard. 
 
Ph2I+ procedure. GC calibrated yields were obtained from the reactions described in Section II and are 
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